(gwye FEN e sin & fen il EF rin)
Temporary relief of nasal congestion, sinusitis, rhinitis, and hay fever; temporary relief of cough associated with upper respiratory tract conditions, especially when associated with dry, nonproductive cough
Hypersensitivity to guaifenesin, phenylephrine, sympathomimetic amines, or any component of the formulation; severe hypertension; severe cardiovascular disease; use with or within 2 weeks of discontinuing MAO inhibitor
Expectorant/decongestant: Oral (Rescon GG): 10 mL every 4-6 hours; maximum: 40 mL/24 hours
Refer to adult dosing.
Expectorant/decongestant: Oral:
Children 2-5 years (Rescon GG): 2.5 mL every 4-6 hours; maximum: 10 mL/24 hours
Children 6-11 years (Rescon GG): 5 mL every 4-6 hours; maximum: 20 mL/24 hours
Children ≥12 years (Rescon GG): Refer to adult dosing
May be taken with or without food. Taking with food, water or milk may help decrease gastric irritation. Some products may contain sodium.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Liquid, oral:
Ed Bron GP: Guaifenesin 100 mg and phenylephrine hydrochloride 5 mg per 5 mL (480 mL) [dye free, ethanol free, sugar free; contains propylene glycol; orange flavor]
Mucinex ‚ ® Cold: Guaifenesin 100 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (480 mL) [contains propylene glycol, sodium 3 mg/5 mL; mixed berry flavor]
Nu-COPD: Guaifenesin 200 mg and phenylephrine hydrochloride 10 mg per 5 mL (480 mL)
Rescon GG: Guaifenesin 100 mg and phenylephrine hydrochloride 5 mg per 5 mL (120 mL [DSC], 480 mL [DSC]) [dye free, ethanol free; contains propylene glycol; wild cherry flavor]
Syrup, oral:
J-Max: Guaifenesin 200 mg and phenylephrine hydrochloride 5 mg per 5 mL (473 mL) [ethanol free, sugar free; contains propylene glycol; strawberry cream flavor]
Triaminic ‚ ® Childrens Chest & Nasal Congestion: Guaifenesin 50 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [contains benzoic acid, propylene glycol, sodium 3 mg/5 mL; tropical flavor]
Tablet, oral:
Ambi 10PEH/400GFN: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg
Fenesin PE IR: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg
Liquibid ‚ ® D-R: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg
Liquibid ‚ ® PD-R: Guaifenesin 200 mg and phenylephrine hydrochloride 5 mg
Medent ‚ ®-PEI: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg
MucaphEd: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg
Mucus Relief Sinus: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg
Nu-COPD: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg
OneTab ¢ „ ¢ Congestion & Cold: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg
Refenesen ¢ „ ¢ PE: Guaifenesin 400 mg and phenylephrine hydrochloride 10 mg
Relcof IR: Guaifenesin 380 mg and phenylephrine hydrochloride 10 mg
Sudafed PE ‚ ® Non-Drying Sinus: Guaifenesin 200 mg and phenylephrine hydrochloride 5 mg
Acetaminophen: May increase the serum concentration of Phenylephrine (Systemic). Monitor therapy
Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patients ability to mount a wheal and flare response. Consider therapy modification
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy
Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination
FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy
Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated. Avoid combination
Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. Avoid combination
Ioflupane I 123: Phenylephrine (Systemic) may diminish the diagnostic effect of Ioflupane I 123. Monitor therapy
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid; Tedizolid. Avoid combination
Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies. Monitor therapy
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists. Monitor therapy
See individual agents.
Disease-related concerns:
- Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.
- Diabetes: Use with caution in patients with diabetes mellitus.
- Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.
- Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.
- Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.
Special populations:
- Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.
Other warnings/precautions:
- Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.
See individual agents.
See individual agents.
- Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
- Patient may experience dizziness, anxiety, insomnia, or fatigue (HCAHPS).
- Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.